- Home
- TRC vs ALT Comparison
TRC vs ALT Comparison
Compare TRC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRC | ALT |
|---|---|---|
| Founded | 1843 | 1997 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.2M | 415.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TRC | ALT |
|---|---|---|
| Price | $17.07 | $4.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 85.3K | ★ 5.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $155.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.90 | $2.90 |
| 52 Week High | $19.39 | $7.73 |
Technical Indicators
Market Signals| Indicator | TRC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 70.21 | 43.90 |
| Support Level | $16.40 | $4.47 |
| Resistance Level | $16.82 | $4.75 |
| Average True Range (ATR) | 0.31 | 0.32 |
| MACD | 0.07 | -0.10 |
| Stochastic Oscillator | 96.40 | 4.96 |
Price Performance
Historical ComparisonAbout TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.